News

The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025

Biocon Biologics remains committed to global standards of Quality and Compliance

Tofacitinib extended-release tablets are a Janus kinase inhibitor indicated for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Ulcerative Colitis

The inspection was concluded with two observations

Yesintek and Yesintek I.V. are indicated for the treatment of moderate to severe plaque psoriasis in adult patients and in pediatric patients

The collaboration is to include a new Insulin Glargine medicine that will benefit patients in the United States by increasing supply of high-quality affordable insulins

Biocon Pharma in partnership with Carnegie Pharmaceuticals LLC, received tentative approval from USFDA

Biocon Biologics and Amgen have executed the settlement agreement to resolve the pending patent litigation

In addition, the USFDA granted provisional interchangeability designation for both BOSAYA and AUKELSO

This investment helps Biocon diversify its manufacturing base, strengthen its supply chain and accelerate the expansion of its global footprint

At the conclusion of the inspection, the USFDA issued a Form 483 with five observations

Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

The Board of Directors of the company at its meeting held August 07, 2025, had considered and approved the same

The total consolidated income of the company decreased by 11.95% at Rs 4,021.60 crore for Q1FY26

Since receiving EU marketing authorization in 2020, Nepexto has earned broad adoption across Europe

KIRSTY will be available as a single-patient-use prefilled pen for subcutaneous use and a multiple-dose vial for subcutaneous and intravenous use

Clinical data showed that both Denosumab biosimilars have comparable safety and efficacy to the reference product

Clinical data showed that both Denosumab biosimilars have comparable quality, safety, and efficacy to the reference product

This achievement reinforces Biocon Biologics’ long-standing commitment to advancing diabetes care and ensuring affordable access to insulin across the country

This approval paves the way for the launch of YESAFILI in Canada, scheduled for July 4, 2025

This collaboration combines the company’s expertise in biosimilars with NCSM’s community outreach to enhance cancer care accessibility and affordability in Malaysia

The Fund Raising Committee of the company at its meeting held on June 16, 2025 authorised the opening of the issue

The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus

Clinical data from the trial program demonstrated that our Ustekinumab biosimilar has comparable safety and efficacy to the originator product

The total consolidated income of the company increased by 12.31% at Rs 4,453.90 crore for Q4FY25

The market access agreements from numerous plans represent over 100+ million lives in the United States

The Board of Directors at its meeting held on April 23, 2025, has inter-alia, considered and approved the same

Maturity of the said Commercial Papers will be on September 30, 2025

This agreement enables the company to launch ‘YESAFILI’ in the United States in the second half of calendar year 2026 or earlier in certain circumstances

The company initiated the Class II recall on March 17, 2025

The approval will further strengthen Biocon’s portfolio of vertically integrated, complex drug products

The approval of JOBEVNE expands Biocon Biologics’ biosimilar oncology portfolio in the United States

The Board of Directors at its meeting held on April 04, 2025, has approved the same

The approval further adds to Biocon’s portfolio of complex drug products

The agreement aims to expand access and affordability of Insulin Aspart in the United States

Biocon Pharma received tentative approval of its ANDA for Rivaroxaban Tablets USP, in 2.5 mg, 10 mg, 15 mg and 20 mg strengths

The drug-device combination will be marketed in the U.K. under the brand names Liraglutide Biocon for diabetes (gVictoza) and Biolide for chronic weight management (gSaxenda)

Yesintek will be available in all the same formulations currently provided by Stelara

YESINTEK is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn’s disease

Total consolidated income of the company decreased by 14.67% at Rs 3856.20 crore for Q3FY25

Post this purchase, Biocon’s stake in BBL will be 90.2%

Biocon achieved an ESG Score of 76 in the Environmental Dimension, 74 in the Social Dimension, and 62 in the Governance & Economic Dimension

This relates to the cGMP inspection conducted by the agency between September 15 - 27, 2024

Ustekinumab, a monoclonal antibody, is approved for the treatment of Psoriasis Vulgaris and Psoriatic Arthritis

The approval further adds to Biocon’s portfolio of complex drug products

The approval is for the generic versions of Victoza to treat Type-2 Diabetes and Saxenda used in the treatment of weight management

Post this transaction, the shareholding of the Company in Syngene shall stand at 52.46%

This is based on a surveillance inspection conducted by the agency between September 23 to 27, 2024

Total consolidated income of the company increased by 0.07% at Rs 3622.90 crore for Q2FY25

This relates to the cGMP inspection conducted by the agency between February 20- 28, 2024

USFDA had conducted the said an inspection between September 23-27, 2024

USFDA had conducted the said an inspection between September 17-27, 2024

Biomm is Brazil’s first and only biotechnology focused company, providing high quality healthcare to patients with chronic conditions and enhancing access to the latest technologies and treatments

The transaction is completed on April 2, 2024

Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus

As a part of this collaboration, Biocon Biologics will continue to leverage Eris’ strong commercial footprint to significantly expand patient access to its world class biosimilars in India

At the conclusion of this inspection, the agency has issued Form 483s with 4 observations

The company has received an order of adjudication imposing a penalty dated February 22, 2024, from the office of Deputy Commissioner of Commercial Taxes, Divisional GST Office, Bangalore

Biocon’s S&P Global ESG score was 63 versus 52 previously

Consolidated total income of the company increased by 49.66% at Rs 4,519.20 crore for Q3FY24

The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024

The approval will further strengthen Biocon’s portfolio of vertically integrated, complex drug products

Earlier in 2023, over 70 Emerging Markets were integrated in July, the North America business transitioned in September and the European business in November

Thereby, Bicara will cease to be an associate company of Biocon

The full transition of Viatris’ biosimilars operations to Biocon Biologics in Europe represents another significant milestone as a world-leading biosimilars company

Consideration received from such sale/disposal is Rs 366 crore including working capital adjustments

The divestment of the non-core branded formulations business units in India is in line

The OAI status may cause delay and/or withholding of pending product approvals or supplements from the facility

Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market

The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway

As a result of the completion of this integration, Biocon Biologics is expected to grow its employee population to over 150 employees in North America

The facility is acquired for a total consideration of $7.7 million

The investment will help Biocon Biologics’ acquisition of the biosimilars business of its partner Viatris

Total consolidated income of the company increased by 58.57% at Rs 3516.10 crore for Q1FY24

These inspections were conducted between July 10, 2023 and July 20, 2023

The company’s subsidiary has completed the integration of the acquired biosimilars business in over 70 countries

Biocon Biologics, which recently announced its acquisition of Viatris’ global biosimilars business, has secured multiple biosimilar approvals in the U.S., Europe, and over 100 countries across the globe

The said Bangalore facility went under an EU GMP inspection in February 2023

The inspection has been concluded with no observations

Total consolidated income of the company increased by 58.67% at Rs 3928.80 crore for Q4FY23

This approval reflects Biocon Biologics’ compliance with the highest international regulatory standards

BBL will have access to 100 million doses of vaccines annually together with the distribution rights to Serum’s Vaccine portfolio

Biocon Biologics was recognized as the winner as it garnered the maximum number of votes from among 70,000 biopharma professionals who participated in the survey

Integrated Core Strategies (Asia) Pte purchased 80,61,599 shares at an average price of Rs 229.26 each share

The maturity date of the said commercial papers was February 22, 2023

Date of maturity of the said NCDs will be on February 21, 2028

The lot has been manufactured by Biocon Pharma and distributed in the US by Iselin-based Biocon Pharma Inc

The shares were sold at an average price of Rs 560 apiece, taking the transaction value at Rs 2,240 crore

The company has received award for its Oral Cancer Screening Program by IHW Council

Biocon Biologics is among the Top 50 Companies among 175 participating companies to feature on this prestigious list

The study will cover several tertiary hospitals specialized in handling UC cases

With this acquisition Biocon Biologics emerges as a world leading biosimilars player with eight commercialized products

Date of maturity of said Commercial Papers will be February 22, 2023

Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe

Debt facility agreement which is classified as a Sustainability-linked Loan amounting to $1.2 billion on November 20, 2022

Total consolidated income of the company increased by 22.56% at Rs 2384.20 crore for Q2FY23

The Board of Directors at its meeting held on November 14, 2022, inter alia, has approved the same

Biocon was the first and only pharmaceutical company from India to be featured on the ASIA IP ELITE list in 2016

Biocon has been ranked 8th on the list this year for three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘has loyal employees

Under the terms of this deal, Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics

There were no critical deficiencies and one deficiency cited under the category ‘Major’

The company has sold a total of 21,789,164 shares, at an average price of Rs 560.04 apiece, in Syngene International

Three observations were cited at the end of the inspection, which the company will be addressing within the stipulated time

The facility, spread across 340,000-square feet, will enhance capabilities manifold to manufacture drug substance of mAbs portfolio